LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung - European Medical Journal

Continue

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD, from Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, discusses data from LUX-lung 7, a randomised, open-label, phase 2b trial comparing afatinib to gefitinib in the first-line treatment setting with patients who are having epidermal growth factor receptor (EGFR) mutation-positive advanced adenocarcinoma of the lung.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given